ClinicalTrials.gg
RecruitingNCT07456371Updated Mar 6, 2026

PIC1 Injection Therapy for Relapsed/Refractory B-NHL

A Phase 1 interventional study of PIC1 Injection in Non-Hodgkin Lymphoma, sponsored by Chongqing Precision Biotech Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Chongqing Precision Biotech Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 196 studies in Lymphoma, Non-Hodgkin with a site in China — 83 open to participants now, 110 under way, 14 of them phase 3. Lymphoma, Non-Hodgkin · China.

Planned enrollment
143rd of 183
18 · median 58
Started
2026
with 12 others
Phase 1
79 of 196
33 open now
Primary completion
2026-12
later than 53 of 109 live
Registered
186th of 196
by date

Among the 196 studies in Lymphoma, Non-Hodgkin with a site in China, this one is the 143rd largest by planned enrollment of the 183 interventional ones that give a count, is one of 13 that started in 2026, is one of 79 in phase 1, reaches primary completion later than 53 of the 109 other live ones, and was the 186th registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

83 of the 196 studies in Lymphoma, Non-Hodgkin with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Lymphoma, Non-Hodgkin with a site in China, or all of them as a file.
02

Study summary

This is an investigator-initiated trial aimed at assessing the safety and efficacy of PIC1 injection in the treatment of relapsed/refractory B-cell Non-Hodgkin Lymphoma.

Read the detailed description

This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo generated Chimeric Antigen Receptor T-cell (CAR-T) therapy in patients with relapsed/refractory B-cell Non-Hodgkin Lymphoma. Upon enrollment, subjects will receive an intravenous infusion of PIC1 injection designed for in vivo CAR-T generation. Following infusion, subjects will be hospitalized for observation and evaluated for safety and efficacy. Subjects will be followed for up to 2 years to assess long-term disease control.

03

Conditions studied

  • Non-Hodgkin Lymphoma

Keywords

  • CAR-T
  • CD19
  • in vivo
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient (or their legally authorized representative) has voluntarily agreed to participate in this clinical trial and has signed the Form (ICF), indicating full understanding of the study's objectives and procedures.
  • Aged 18 to 75 years, regardless of gender.
  • or cytologically confirmed B-cell Non-Hodgkin Lymphoma (NHL) according to the WHO 2017 classification, including the following subtypes:

    1. Diffuse Large B-Cell Lymphoma (DLBCL): Including DLBCL, not otherwise specified (DLBCL, NOS); DLBCL associated with chronic inflammation; Primary Cutaneous DLBCL, leg type; and EBV-positive DLBCL, NOS.
    2. High-Grade B-Cell Lymphoma (HGBL): Including HGBL, NOS; and HGBL with MYC and BCL2 and/or BCL6 rearrangements.
    3. Primary Mediastinal Large B-Cell Lymphoma.
    4. T-cell/Histiocyte-rich Large B-Cell Lymphoma.
    5. Transformed DLBCL: DLBCL transformed from prior lymphomas (e.g., Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Marginal Zone Lymphoma).
    6. Follicular Lymphoma Grade 3b (FL3b).
    7. Mantle Cell Lymphoma.
  • Patients must have received adequate prior therapy including an anti-CD20 monoclonal antibody and an anthracycline, unless or intolerant (i.e., CD20-negative status, intolerance to anti-CD20 mAb, or contraindication to anthracyclines). Patients must meet the definition of (R/R) disease:

    1. Relapsed: Disease progression or recurrence after achieving a Complete Response (CR) to standard therapy.
    2. Refractory: Best response of Stable Disease (SD) after at least 4 cycles of therapy or at least 2 cycles of last-line therapy (≥2nd line), with SD duration ≤6 months after the last dose; or best response of Progressive Disease (PD) to the last treatment.
    3. No response, disease progression, or relapse after Stem Cell Transplantation (ASCT).
    4. Patients with transformed lymphoma who received chemotherapy prior to transformation and subsequently failed to achieve response, progressed, or relapsed after salvage therapy post-transformation.
  • CD19 positivity confirmed by immunohistochemistry (IHC) or flow cytometry.
  • performance status of 0 or 1.
  • Estimated of ≥12 weeks.
  • At least one per the 2014 Lugano Criteria:

    1. For nodal lesions: Longest diameter >1.5 cm.
    2. For extranodal lesions: Longest diameter >1.0 cm.
  • Adequate major organ function defined as:

    1. Cardiac function: (LVEF) ≥40% by echocardiogram.
    2. Renal function: Serum creatinine ≤2.0 × or ≥50 mL/min (calculated by Cockcroft-Gault formula).
    3. Hepatic enzymes: and AST ≤3.0 × ULN (or ≤5.0 × ULN for subjects with hepatic involvement).
    4. : Total bilirubin ≤2.0 × ULN (or ≤3.0 × ULN for subjects with Gilbert's syndrome).
    5. Oxygenation: Oxygen saturation (SpO2) ≥ 92% while breathing room air.
    6. Hematology: ≥ 1.0 × 10\^9/L; count ≥ 75 × 10\^9/L; ≥ 80 g/L. (For subjects with bone marrow involvement: Neutrophil ≥ 0.5 × 10\^9/L and Platelet count ≥ 50 × 10\^9/L.)
  • Women of must have a negative pregnancy test. All subjects must agree to use a highly effective method of from the time of signing the ICF until 1 year after the infusion of the product.

Exclusion criteria

Exclusion Criteria:

  • Received prior Chimeric Antigen Receptor T-cell (CAR-T) therapy or any other gene-modified cell therapy before screening.
  • Received any of the following anti-tumor therapies prior to PIC1 infusion:

    1. medications (e.g., chemotherapy, targeted therapy) within 14 days or 5 half-lives (whichever is longer) before infusion. (excluding lymphodepleting chemotherapy and intrathecal chemotherapy for CNS lymphoma. And intrathecal chemotherapy must be discontinued at least 1 week prior to PIC1 infusion.)
    2. Radiation therapy within 14 days before infusion.
  • Has any of the following cardiac conditions:

    1. (NYHA) Class III or IV congestive heart failure.
    2. Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months prior to enrollment.
    3. ventricular arrhythmias, or a history of unexplained syncope (excluding cases caused by vasovagal reactions or dehydration).
    4. History of severe non-ischemic cardiomyopathy.
  • Has an active or uncontrolled infection requiring systemic treatment within 1 week prior to screening.
  • Has Grade 2-4 acute or moderate-to-severe chronic GVHD within 4 weeks prior to screening.
  • Has experienced a cerebrovascular accident or seizure within 6 months prior to screening.
  • Has experienced a deep vein thrombosis or arterial embolism event within 6 months prior to screening.
  • Has a history of other except for: tumors with no evidence of active disease where treatment was completed >2 years ago; adequately treated carcinoma in situ of the cervix; basal cell or squamous cell skin cancer; radical prostatectomy; radical ductal carcinoma in situ.
  • Received a within 4 weeks prior to screening.
  • Any other condition that, in the opinion of the Investigator, makes the subject unsuitable for participation in this study.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    PIC1 Injection

    Biological: PIC1 Injection

Interventions

  • BiologicalPIC1 Injection

    Three dose groups (1.0×10\^9 TU, 2.0×10\^9 TU, 4.0×10\^9 TU) were set up, starting from the low dose group climbing to explore the safe and effective dose.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs) after infusion

    Types, frequency and severity of adverse events.

    Time frame: 1 month

Secondary outcomes

  1. Overall Response Rate (ORR)

    The proportion of patients achieving a Complete Response (CR) and Partial Response (PR) post-treatment, as assessed per the Lugano 2014 criteria.

    Time frame: 3 months

  2. Best Overall Response (BOR)

    The proportion of patients achieving a Complete Response (CR) or Partial Response (PR) post-treatment.

    Time frame: 3 months

  3. Duration of Response (DOR)

    The time interval from the first documentation of CR or PR to the first documentation of disease progression (PD) or death from any cause, whichever occurs first. This metric applies only to subjects who achieve a confirmed response.

    Time frame: 3 months

  4. Progression-Free Survival (PFS)

    The time from the initiation of PIC1 treatment to the first occurrence of disease progression or death from any cause, whichever occurs first.

    Time frame: 3 months

  5. Overall Survival (OS)

    The time from the initiation of PIC1 treatment to death from any cause.

    Time frame: 3 months

  6. The maximum concentration (Cmax)

    The maximum concentration (Cmax) of CAR-T cells in peripheral blood resulting from in vivo expansion after infusion.

    Time frame: 1 month

  7. The time to maximum concentration (Tmax)

    The time to reach the maximum concentration (Cmax) of CAR-T cells in peripheral blood resulting from in vivo expansion after infusion.

    Time frame: 1 month

  8. AUC 28d

    The area under the concentration-time curve of CAR-T cells in peripheral blood over the 28-day period (AUC 28d) after infusion.

    Time frame: 1 month

  9. Serum cytokine levels

    Serum cytokine levels (such as IL-6, IL-10, TNF-α, IFN-γ) at various time points after infusion.

    Time frame: 1 month

  10. Peripheral blood lymphocyte subsets

    Peripheral blood lymphocyte subsets (T, B, and NK cell proportions or counts) at various time points after infusion.

    Time frame: 3 months

Other outcomes

  1. Viral vector sequences

    Viral vector sequences will be detected in blood, saliva, urine, and fecal samples until two consecutive negative results are obtained, to evaluate the potential risk of environmental shedding of the viral vector.

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's planned 9 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 6, 2026
StartEst.
Mar 2026
Primary completionEst.
Dec 2026
CompletionEst.
Feb 2029
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07456371
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Mar 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Feb 2029 (estimated)
Last update
Mar 6, 2026

Study contacts

Jia Wei
Contact
jiawei@tjh.tjmu.edu.cn
+86 13986102084

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion